clonazepam has been researched along with methylphenidate in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Zetler, G | 2 |
| Behar, D; Schaller, JL | 1 |
| Ghaziuddin, N; Iqbal, A; Khetarpal, S | 1 |
| Carter, G | 1 |
| Bachoud-Lévi, AC; Blasco-Amaro, JA; Capuano, A; Isabel-Gómez, R; Martín-Gómez, C; Nou-Fontanet, L; Ortigoza-Escobar, JD; Zorzi, G | 1 |
2 review(s) available for clonazepam and methylphenidate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Systematic review of drug therapy for chorea in NXK2-1-related disorders: Efficacy and safety evidence from case studies and series.
Topics: Carbidopa; Chorea; Clonazepam; Humans; Levodopa; Methylphenidate; Tetrabenazine | 2023 |
8 other study(ies) available for clonazepam and methylphenidate
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Antistereotype effects of ceruletide and some neuroleptics differentiated by interactions with clonazepam, muscimol, scopolamine and clonidine.
Topics: Animals; Antipsychotic Agents; Ceruletide; Clonazepam; Clonidine; Clopenthixol; Fluphenazine; Haloperidol; Male; Methylphenidate; Mice; Muscimol; Scopolamine; Sincalide; Stereotyped Behavior | 1986 |
Neuroleptic-like effects of ceruletide and cholecystokinin octapeptide: interactions with apomorphine, methylphenidate and picrotoxin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Blepharoptosis; Body Temperature; Ceruletide; Clonazepam; Drug Antagonism; Haloperidol; Male; Methylphenidate; Mice; Peptide Fragments; Picrotoxin; Sincalide | 1983 |
Treating comorbid ADHD, major depression, and panic.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonazepam; Depressive Disorder, Major; GABA Modulators; Humans; Male; Methylphenidate; Panic Disorder | 1999 |
Myoclonus during prolonged treatment with sertraline in an adolescent patient.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Clonazepam; Female; Humans; Methylphenidate; Myoclonus; Pseudotumor Cerebri; Risk Factors; Sertraline | 2001 |
Animal behavior case of the month. Hyperactivity.
Topics: Animals; Anti-Anxiety Agents; Behavior Therapy; Behavior, Animal; Clonazepam; Dogs; Male; Methylphenidate; Noise; Phobic Disorders; Psychomotor Agitation | 2011 |